Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (171)	2/5/1998 1:15:00 AM
From: ahhaha	Respond to of 399

You mean chemical discovery, not drug discovery. An isomer of a drug is not a drug. An engineered molecular equivalent of a drug is not a drug because you don't know that it is equivalent or equivalent in implied functionality. The larger the molecule the greater is the uncertainty. Now those responsible for determining whether the pseudo-equivalent has the proven and reliable effect may not wish to take the risk, time, and effort to determine that.What's more the molecular complex may have attributes where it acts like it should but in non-standard environmento-chemical regimes, it acts like a potent toxin. Do you want to test some of their spins? Even if the engineered chemical is an intermediary providing supporting chemical reactions in a theoretically stable regime, since the value of the chemical goes up with its size, you can't be sure that the resulting substance is what it was when the synthetic helper chemical wasn't introduced. All it takes is one of these "infinitude" of Wheel possibilities to poison someone to send this stock into the basement. How many collaborations do you think they'll be worth in that case? The company Wheel may not even be directly responsible, but suddenly Wall Street will discover the downside. No doubt this kind of thing looms everywhere in biotech, but there are better ways to approach the subject and control the risk.